drugset / Trial / NCT02951117
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter clinical trial designed to evaluate the safety and potential efficacy of venetoclax and ABBV-838 combination therapy with dexamethasone in participants with relapsed or refractory multiple myeloma (MM) who have received 2 or more prior lines of therapy for multiple myeloma (MM). The study will consist of 2 arms: Arm A and Arm B (if applicable). Each arm will have a dose escalation and dose expansion portion.
Timeline
- Start
- 2017-08-31
- Primary completion
- 2020-07-28
- Completion
- 2021-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZINTUXIZUMAB VEDOTIN | Unknown | 4 mg/kg | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | — |
| Subject | Venetoclax | Small molecule | 800 mg | — |
| Background | Dexamethasone | Small molecule | 40 mg | Intravenous |